patients were treated with concurrent chemoradiation followed by brachytherapy. The median follow-up period was 47 months. The three-year DFS and OS were 13.3% and 13.3% respectively.

**Conclusion** CCCC has a poor prognosis, stage for stage compared to other histologies. The FIGO stage, tumour size, lymphovascular space invasion and pelvic node status were factors that predicted the prognosis. Adjuvant radiotherapy or chemoradiotherapy have a limited role in the treatment of this rare cancer.

**Disclosures** The authors have no potential conflict of interest to disclose.

---

**Abstracts**

**285 Efficacy of a multi-ingredient Coriolus versicolor-based vaginal gel in HPV+ women older than 40 years: sub-analysis of Paloma clinical trial**

Y. Gaslín, 1L. Serrano, 2A. Carlos López, 2S. González, 1S. Palacios, 2D. Dexeus, 1P. Coronado, 1S. Jesús de la Fuente, 1A. Antonio López, 2C. Vanrell, 2P. Health, 1C. Médico Gabinete Velázquez, 1Hospital Quirónsalud, 6Instituto Palacios Salud Y Medicina de la Mujer, 7Women’s Health Institute, 6Hospital Clínico San Carlos, 1Hospital Universitario Infantia Leonor, 8Hospital Universitario de Alcalatén, 2Hospital de la Santa Creu i Sant Pau

**Introduction/Background** HPV clearance and resolution of cervical HPV-dependent lesions become important in peri and postmenopausal women. The objective of this sub-analysis was to evaluate the effect of the Papilocare®, a multi-ingredient Coriolus versicolor-based vaginal gel, on the normalization of cervical HPV-dependent atypia (ASCUS and LSIL) and associated colposcopic alterations in women older than 40 years.

**Methodology** Paloma clinical trial (ClinicalTrials.gov NCT04002154) was a multicenter, randomized, open-label, parallel-group, usual practice-controlled clinical trial. Unvaccinated HPV positive women aged between 30–65 with cytology of ASCUS or LSIL and concordant colposcopic image were randomized into 3 groups: A) Papilocare® 1 cannula/day for 1 month + 1 cannula/alternate days for 3 months; B) Papilocare® 1 cannula/day for 3 months + 1 cannula/alternate days for 3 months; C) Control group: no treatment. The primary endpoint,% of patients with normal cytology and concordant colposcopy after 6 months of treatment in the total population, high-risk HPV (16,18,31,33,35,39,45,51,52,56,58,59,68) and very high-risk HPV (patients infected by any combination of 16, 18 and 31) subpopulations. Pap smear evaluations were blind and centrally conducted by an independent researcher at the IECM laboratory (Lugo, Spain). Papilocare® arms (A+B) were combined as treatment group.

**Results** A total of 41 out of 84 evaluated patients included in Paloma trial were older than 40y [mean (SD) age: 47.71 (5.56)], of which 30 and 13 were high-risk HPV and 16-18-31 HPV patients, respectively. At 6 months, normal cytology and concordant colposcopic image was observed in 92%, 90% and 75% of patients treated with Papilocare® vs 50%, 33% and 40% of patients in control group, in the total population, and high-risk and 16-18-31 subpopulations (p=0.0066; p=0.0031; p=0.2929, Fisher test) respectively.

**Conclusion** Papilocare® showed a robust efficacy in normalizing cervical HPV lesions in women older than 40 years old, with a statistically significant difference vs control group in the total and high-risk populations.

**Disclosures**


All other authors have declared no conflicts of interest.

---

**287 Real-life efficacy of a multi-ingredient Coriolus versicolor-based vaginal gel in high-risk HPV patients: interim analysis**

Y. Gaslín, 2J. Cortés, 3J. de Santiago, 4M. Pilar Sanjuán, 5M. Agenjo, 2G. Fiol, 2C. García, 4M. Guereu, 2P. Hernández, 1Procare Health; Private Practice; 2Centro Oncológico MD Anderson; 2Clínica Ginemed; 3Hospital Sanitas La Zarzuela; 4Hm San Francisco; 5Hospital La Fe

10.1136/ijgc-2020-ESGO.20

**Introduction/Background** Real-life studies inform on the ‘effectiveness’ of a treatment what is intended to do in routine circumstances. The aim of this study is to evaluate the efficacy of Papilocare® - a multi-ingredient Coriolus versicolor-based vaginal gel- on repairing high-risk (HR) HPV-dependent low-degree cervical lesions and HR-HPV clearance in real-life practice.

**Methodology** Observational, multicenter, prospective, one-cohort study (PAPILOBS study ClinicalTrial.gov: NCT04199260). Currently recruiting 300 vaccinated or not HPV-positive women aged > 25y with Pap smear of ASCUS or LSIL and concordant colposcopy during routine clinical visits in Spain. Patients are treated with Papilocare® 1 cannula/day for 21 days the first month + 1 cannula/alternate days for 5 months. After this 6-month period, patients with altered cytology and/or HPV persistency are treated for a 6-month extension treatment period with the same dosage.

Interim analysis of HR-HPV patients with normal Pap smear and concordant colposcopy image (primary endpoint) and patient with HR-HPV cleared (patients with total clearance or partial clearance together with negative Pap smear and normal colposcopy) at 6/12 months is presented. The study was approved by the ethical committee of Public University Hospital of Puerta de Hierro (Madrid). Informed consent was signed by all patients.

**Results** At 6 months, data of 148 and 146 patients for Pap smear/colposcopy and HR-HPV presence, respectively, were available. 67.6% of patients (100/148) had negative Pap smear and normal colposcopy. HR-HPV clearance was observed in 58,9% of patients (86/146). Data of 46 and 44 patients included in the 6-month extension treatment period for Pap smear/colposcopy and HR-HPV presence, respectively, were available. At 12 months, 78.3% (36/46) of patients had negative Pap smear and concordant colposcopy and HR-HPV clearance was observed in 70.5% (31/44). Considering all study period, 77% (114/148) and 72.6% (106/146) of patients repaired HR-HPV-dependent cervical lesions and cleared HR-HPV, respectively.

**Conclusion** In this interim analysis, repairing of HR-HPV-dependent low-degree cervical lesions and clearing HR-HPV, in real life conditions, was achieved after 6-month treatment.
Efficacy of a multi-ingredient Coriolus versicolor-based vaginal gel in high-risk HPV+ patients: Results of different studies

Introduction/Background To evaluate the consistency of the efficacy of a non-hormonal multi-ingredient Coriolus versicolor-based vaginal gel, Papilocare®, on HPV clearance in patients infected by high-risk HPV (HR-HPV) in several studies.

Methodology Results at 6 months from independent observational non-comparative studies carried out in three different public centers and in one private center were compared to results from both a randomized, open, parallel and controlled clinical trial comparing the Papilocare® vs wait and see approach (The Paloma RCT) and an observational, multicenter, prospective, one-cohort study (Papilobs real-life study). Two prospective (Vigo and Bari studies) and two retrospective studies (Coruña and Hospital study) have been performed.

- Vigo study: HPV clearance of 25 patients infected by HPV 16 and/or 18 was evaluated as a secondary endpoint.
- Bari study: HPV clearance of 98 HR-HPV patients was evaluated as primary endpoint.
- Coruña study: 57 medical records of patients with HR-HPV were analyzed. HPV clearance was evaluated as primary endpoint.
- Hospital study: Data of HR-HPV patients were evaluated. Primary endpoint: composite efficacy variable (percentage of patients with normal cytology and/or HPV clearance).

- Papilobs study: Interim data of 148 HR-HPV patients is presented. HR-HPV clearance was evaluated as a secondary endpoint.

- Paloma RCT: 66 HR-HPV patients were evaluated. Percentage of patients with HR-HPV clearance was assessed as a secondary endpoint.

Results After the 6-month treatment period, 48% and 57% of patients cleared HPV 16–18 and HR-HPV in Vigo and Bari studies, respectively. A reduction of 58% was observed in number of HR-HPV patients (Coruña) and 72.5% of patients negativized cytology and/or cleared HR-HPV (Hospitalita) (p≤0.0001 vs baseline for all results, Chi-square). In the Paloma RCT, HR-HPV clearance was observed in 63% of patients treated with Papilocare® vs 40% in the control group. Similar rate of 59% HR-HPV clearance was observed in the interim analysis of the Papilobs study.

Conclusion Papilocare® has shown significant and consistent rates of HR-HPV clearance ranging from 50% to 70% in the 6 different studies. This high consistently rate of HR-HPV clearance should be further confirmed in ongoing studies.

Disclosure Funding: Procace Health. Disclosures: J.Cortés, S. Palacios, D. Dexeus, L. Serrano: Advisory/Consulting Role and Speakers at Procace Health. Y.Gaslain: CEO of Procace Health. All other authors have declared no conflicts of interest.